| Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region H Mehanna, T Beech, T Nicholson, I El‐Hariry, C McConkey, V Paleri, ... Head & neck 35 (5), 747-755, 2013 | 998 | 2013 |
| A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma C Wülfing, JPH Machiels, DJ Richel, MO Grimm, U Treiber, MR De Groot, ... Cancer 115 (13), 2881-2890, 2009 | 263 | 2009 |
| Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study SA Bhide, M Davies, K Burke, HA McNair, V Hansen, Y Barbachano, ... International Journal of Radiation Oncology* Biology* Physics 76 (5), 1360-1368, 2010 | 257 | 2010 |
| A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non–small cell lung cancer MA Socinski, J Goldman, I El-Hariry, M Koczywas, V Vukovic, L Horn, ... Clinical cancer research 19 (11), 3068-3077, 2013 | 256 | 2013 |
| Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non–small cell lung cancer J Sang, J Acquaviva, JC Friedland, DL Smith, M Sequeira, C Zhang, ... Cancer discovery 3 (4), 430-443, 2013 | 256* | 2013 |
| Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. A Valizadeh, AJ Karayiannakis, I El-Hariry, W Kmiot, M Pignatelli The American journal of pathology 150 (6), 1977, 1997 | 217 | 1997 |
| Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck JM Del Campo, R Hitt, P Sebastian, C Carracedo, D Lokanatha, J Bourhis, ... British journal of cancer 105 (5), 618-627, 2011 | 121 | 2011 |
| A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with … JW Goldman, RN Raju, GA Gordon, I El-Hariry, F Teofilivici, VM Vukovic, ... BMC cancer 13, 1-10, 2013 | 120 | 2013 |
| Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future … K Harrington, A Berrier, M Robinson, E Remenar, M Housset, ... European journal of cancer 49 (7), 1609-1618, 2013 | 119 | 2013 |
| Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3 PN Ganji, W Park, J Wen, H Mahaseth, J Landry, AB Farris, F Willingham, ... Angiogenesis 16, 903-917, 2013 | 116 | 2013 |
| Vicia faba agglutinin, the lectin present in broad beans, stimulates differentiation of undifferentiated colon cancer cells M Jordinson, I El-Hariry, D Calnan, J Calam, M Pignatelli Gut 44 (5), 709-714, 1999 | 112 | 1999 |
| Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial A Ravaud, R Hawkins, JP Gardner, H Von der Maase, N Zantl, P Harper, ... Journal of Clinical Oncology 26 (14), 2285-2291, 2008 | 111 | 2008 |
| A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer K Jhaveri, S Chandarlapaty, D Lake, T Gilewski, M Robson, S Goldfarb, ... Clinical breast cancer 14 (3), 154-160, 2014 | 110 | 2014 |
| Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of … K Harrington, S Temam, H Mehanna, A D'Cruz, M Jain, I D'Onofrio, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 101 | 2015 |
| Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck KJ Harrington, IA El-Hariry, CS Holford, A Lusinchi, CM Nutting, D Rosine, ... Journal of clinical oncology 27 (7), 1100-1107, 2009 | 96 | 2009 |
| Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer SA Bhide, S Gulliford, R Kazi, I El-Hariry, K Newbold, KJ Harrington, ... Radiotherapy and Oncology 93 (3), 539-544, 2009 | 94 | 2009 |
| HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors N Spector, W Xia, I El-Hariry, Y Yarden, S Bacus Breast Cancer Research 9, 1-8, 2007 | 90 | 2007 |
| Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial P Hammel, P Fabienne, L Mineur, JP Metges, T Andre, ... European Journal of Cancer 124, 91-101, 2020 | 82 | 2020 |
| Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC) A Ravaud, J Gardner, R Hawkins, H Von der Maase, N Zantl, P Harper, ... Journal of Clinical Oncology 24 (18_suppl), 4502-4502, 2006 | 78 | 2006 |
| Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer DA Proia, C Zhang, M Sequeira, JP Jimenez, S He, N Spector, GI Shapiro, ... Clinical Cancer Research 20 (2), 413-424, 2014 | 71 | 2014 |
